11th Apr 2006 15:30
FIRST QUARTER 2006 RESULTS DATE NOTIFICATION27 April 2006Basingstoke, UK and Philadelphia, US - 11 April 2006 - Shire plc (LSE: SHP,NASDAQ: SHPGY, TSX: SHQ) will announce first quarter 2006 earnings on Thursday27 April 2006.Results press release will be 12:00 GMT / 07:00 ET issued at: Investor conference call time: 14:00 GMT / 09:00 ET Live conference call for investors:Matthew Emmens, Chief Executive Officer and Angus Russell, Chief FinancialOfficer will host the live conference call for investors at 14:00 GMT/9:00 ET.Please RSVP [email protected] (T: +44 (0)1256 894 160) for this conferencecall.The details of the live conference call are as follows:UK dial in 0800 953 1444 (free call) US / Canada dial in US: 1 866 295 3947 (toll free)/ Canada: 1 866 476 5524 International dial in + 44 (0) 1452 561 394 Password/Conf ID 7860599 Live Webcast:The call will also be available live over the Internet via audio webcast,accessible through www.shire.com in the investor relations section. A slidepresentation to accompany the call will also be available on the Shire website.Replay:A replay of the presentation will be available for two weeks. Details are asfollows:UK dial in 0845 245 5205 International dial in +44 (0) 1452 55 00 00 Pin code 7860599# Webcast replay www.shire.com, in the investor relations section If you have any problems accessing this, please contact: Souheil Salah on: +44(0) 1256 894160For further information please contact:Investor Relations Souheil Salah (Rest of the World) +44 1256 894 160 Heidi Wunder (North America) +1 484 595 8970 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system, gastrointestinal, generalproducts and human genetic therapies - all being areas in which Shire has acommercial presence. The structure is sufficiently flexible to allow Shire totarget new therapeutic areas to the extent opportunities arise throughacquisitions. Shire believes that a carefully selected portfolio of productswith strategically aligned and relatively small-scale sales forces will deliverstrong results. Shire's strategy is to develop and market products forspecialty physicians. Shire's in-licensing and merger and acquisition effortsare focused on products in niche markets with strong intellectual propertyprotection either in the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Registered in England 2883758 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire